Palatin Technologies (PTN) AI Stock Analysis

• Market Cap: $5.72M
• Dividend Yield: N/A
• Average Volume (3M): 2.99K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.83
• Revenue Growth: 271.10%
• EPS Growth: 87.20%
• Country: US
• Employees: 30
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 4.26
• Shares Outstanding: 973,291
• 10 Day Avg. Volume: 2,746
• 30 Day Avg. Volume: 2,993
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: 0.72
• Enterprise Value/Revenue: 0.46
• Enterprise Value/Gross Profit: 0.48
• Enterprise Value/Ebitda: -0.91
• 1Y Price Target: $50.00
• Price Target Upside: 83.49% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $0.00 ▼(-100.00% Downside)

Palatin Technologies' overall score is heavily impacted by its poor financial performance and the negative corporate event of potential delisting. While some technical indicators suggest short-term bullish momentum, the overall bearish trend and unfavorable valuation metrics underscore significant risks. The company must address its financial instability to improve its market position.

Positive Factors

Product Portfolio

Palatin's focus on targeted receptor-specific therapeutics, like Vyleesi, positions it well in niche markets, potentially driving long-term growth.

Strategic Partnerships

Strategic partnerships for product distribution and marketing enhance Palatin's market reach and provide diversified revenue streams, supporting sustainable growth.

Governance Improvements

Recent governance changes, like director elections and reverse stock split, may strengthen corporate structure and improve stakeholder confidence, aiding long-term stability.

Negative Factors

Financial Instability

Persistent financial losses and negative equity raise concerns about Palatin's solvency and ability to sustain operations without external financing.

Delisting Risk

The potential delisting from NYSE American LLC poses a significant risk to Palatin's market presence and could limit access to capital markets.

Weak Cash Generation

Weak cash generation and reliance on external financing indicate potential liquidity issues, limiting Palatin's ability to invest in growth and innovation.

Palatin Technologies Business Overview & Revenue Model

Company Description

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

How the Company Makes Money

Palatin Technologies generates revenue through the commercialization of its pharmaceutical products, primarily Vyleesi. Revenue streams include product sales, licensing agreements, royalties, and milestone payments from strategic partnerships and collaborations with other pharmaceutical companies. The company has established partnerships for the distribution and marketing of Vyleesi in various regions, which contributes to its earnings. Additionally, Palatin may receive government grants or funding for its research and development initiatives, although these are not primary revenue sources.

Palatin Technologies Financial Statement Overview

Summary

Palatin Technologies is facing significant financial challenges across all verticals. The income statement shows persistent losses, the balance sheet reflects negative equity suggesting potential solvency issues, and cash flow statements reveal weak cash generation with a heavy reliance on external financing.

Income Statement

The income statement reflects significant challenges, with consistent net losses and negative EBIT margins. Gross profit margin showed improvement, but revenue growth is inconsistent, with a significant decline in the TTM period. Overall, the company struggles to achieve profitability, impacting its financial health.

Balance Sheet

The balance sheet is concerning, with negative stockholders' equity indicating potential solvency issues. The debt-to-equity ratio is undefined due to negative equity, and total assets have significantly decreased. The company’s high liabilities relative to assets highlight financial instability.

Cash Flow

Cash flow analysis shows persistent negative free cash flow and operating cash flow. The company relies on financing activities to manage cash needs. Free cash flow to net income and operating cash flow to net income ratios are negative, suggesting cash generation issues.

Breakdown	TTM	Dec 2025	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	8.85M	―	0.00	4.49M	4.85M	1.47M
Gross Profit	8.63M	―	-258.92K	4.39M	4.44M	1.25M
EBITDA	-4.51M	―	-17.03M	-29.38M	-28.40M	-35.68M
Net Income	-4.81M	―	-17.31M	-29.74M	-24.04M	-36.20M
Balance Sheet
Total Assets	8.61M	―	3.27M	10.74M	17.94M	36.07M
Cash, Cash Equivalents and Short-Term Investments	1.27M	―	2.56M	9.53M	10.98M	29.94M
Total Debt	132.45K	―	163.78K	590.34K	1.05M	1.15M
Total Liabilities	8.22M	―	8.04M	10.85M	19.92M	19.80M
Stockholders Equity	396.40K	―	-4.78M	-111.50K	-1.98M	16.27M
Cash Flow
Free Cash Flow	-15.91M	―	-21.31M	-31.50M	-28.85M	-30.18M
Operating Cash Flow	-15.91M	―	-21.31M	-31.46M	-28.42M	-29.92M
Investing Cash Flow	3.13M	―	3.13M	12.45M	-3.43M	-261.37K
Financing Cash Flow	11.67M	―	11.21M	20.55M	9.90M	18.36K

Palatin Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 27.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTN, the sentiment is Positive. The current price of 27.25 is above the 20-day moving average (MA) of 18.75, above the 50-day MA of 11.78, and above the 200-day MA of 13.27, indicating a bullish trend. The MACD of 3.91 indicates Negative momentum. The RSI at 64.79 is Neutral, neither overbought nor oversold. The STOCH value of 73.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PTN.

Palatin Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IBIO	55 Neutral	$63.19M	―	-54.50%	―	185.71%	79.03%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BOLT	49 Neutral	$9.67M	-0.19	-81.97%	―	-46.88%	34.83%
BRTX	48 Neutral	$11.81M	―	-207.73%	―	1.70%	-111.67%
PTN	46 Neutral	$5.72M	-0.16	―	―	271.10%	87.20%
ADXN	46 Neutral	$9.83M	―	-71.27%	―	-72.15%	-223.62%
PHIO	42 Neutral	$14.10M	-0.59	-107.58%	―	―	83.95%

Palatin Technologies Corporate Events

Palatin Technologies Stockholders Approve Key Governance Changes

On July 25, 2025, Palatin Technologies held its annual meeting of stockholders to vote on several key issues, including the election of directors and an amendment to effect a reverse stock split. The stockholders approved the election of four directors and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2025. Additionally, they approved the issuance of shares upon the exercise of certain stock purchase warrants and an amendment to increase the number of shares available for equity awards. These decisions are expected to impact the company’s financial structure and governance, potentially affecting its market positioning and stakeholder interests.

The most recent analyst rating on (PTNT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Palatin Technologies stock, see the PTNT Stock Forecast page.

Palatin Technologies Faces NYSE Delisting Proceedings

On July 7, 2025, Palatin Technologies received a notification from NYSE American LLC regarding the initiation of delisting proceedings for the company’s common stock. A hearing was held on June 18, 2025, and the decision to delist was affirmed by a Listing Qualifications Panel. Palatin Technologies plans to appeal this decision and is working to address the listing deficiencies before the full Committee for Review, expected in late August or September 2025.

The most recent analyst rating on (PTNT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Palatin Technologies stock, see the PTNT Stock Forecast page.

Palatin Technologies Raises $340K in Private Placement

On June 10, 2025, Palatin Technologies entered into a securities purchase agreement with accredited investors to sell Series D Convertible Preferred Stock and Series I common stock purchase warrants in a private placement, closing on June 13, 2025, raising $340,000 for working capital. The Preferred Stock, convertible into common stock, and warrants were sold at $0.11 per share, with key company executives participating as purchasers. The company plans to file a registration statement for resale of shares and warrants, impacting its financial strategy and shareholder structure.

The most recent analyst rating on (PTNT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Palatin Technologies stock, see the PTNT Stock Forecast page.